| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 30 | 2023 | 236 | 8.580 |
Why?
|
| Receptors, Opioid | 26 | 2023 | 38 | 8.210 |
Why?
|
| Receptors, Opioid, mu | 24 | 2023 | 51 | 5.630 |
Why?
|
| Pruritus | 17 | 2020 | 58 | 5.280 |
Why?
|
| Opioid Peptides | 14 | 2021 | 28 | 5.040 |
Why?
|
| Pain | 20 | 2023 | 282 | 4.470 |
Why?
|
| Analgesics | 19 | 2023 | 125 | 3.840 |
Why?
|
| Morphine | 16 | 2022 | 57 | 2.970 |
Why?
|
| Spinal Cord | 9 | 2016 | 139 | 2.960 |
Why?
|
| Animals | 89 | 2023 | 7297 | 2.950 |
Why?
|
| Naltrexone | 24 | 2022 | 38 | 2.890 |
Why?
|
| Macaca mulatta | 46 | 2021 | 322 | 2.590 |
Why?
|
| Narcotic Antagonists | 20 | 2015 | 50 | 2.430 |
Why?
|
| Dose-Response Relationship, Drug | 39 | 2022 | 641 | 2.420 |
Why?
|
| Receptors, Opioid, kappa | 17 | 2015 | 40 | 2.310 |
Why?
|
| Carboxylic Ester Hydrolases | 12 | 2012 | 15 | 2.230 |
Why?
|
| Cocaine | 15 | 2016 | 262 | 2.230 |
Why?
|
| Behavior, Animal | 12 | 2015 | 264 | 1.910 |
Why?
|
| Receptors, Bombesin | 5 | 2020 | 8 | 1.650 |
Why?
|
| Hyperalgesia | 9 | 2019 | 88 | 1.610 |
Why?
|
| Gastrin-Releasing Peptide | 4 | 2015 | 7 | 1.610 |
Why?
|
| Male | 70 | 2022 | 17768 | 1.420 |
Why?
|
| Receptors, Opioid, delta | 6 | 2022 | 17 | 1.390 |
Why?
|
| Buprenorphine | 5 | 2019 | 18 | 1.310 |
Why?
|
| Injections, Spinal | 14 | 2019 | 124 | 1.240 |
Why?
|
| Azabicyclo Compounds | 5 | 2019 | 12 | 1.230 |
Why?
|
| Piperazines | 6 | 2022 | 56 | 1.220 |
Why?
|
| Spiro Compounds | 6 | 2013 | 8 | 1.170 |
Why?
|
| RNA, Messenger | 6 | 2019 | 514 | 1.160 |
Why?
|
| Capsaicin | 8 | 2009 | 30 | 1.140 |
Why?
|
| Benzamides | 4 | 2022 | 54 | 1.090 |
Why?
|
| Respiratory Insufficiency | 3 | 2023 | 61 | 1.080 |
Why?
|
| Disease Models, Animal | 12 | 2022 | 980 | 1.030 |
Why?
|
| Thalamus | 4 | 2018 | 39 | 1.010 |
Why?
|
| Bombesin | 6 | 2020 | 8 | 0.990 |
Why?
|
| Imidazoles | 4 | 2013 | 104 | 0.970 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 49 | 0.940 |
Why?
|
| Pain Measurement | 17 | 2013 | 360 | 0.940 |
Why?
|
| Female | 45 | 2022 | 18114 | 0.920 |
Why?
|
| Brain-Derived Neurotrophic Factor | 3 | 2009 | 36 | 0.920 |
Why?
|
| Ligands | 7 | 2021 | 81 | 0.910 |
Why?
|
| Cannabinoids | 2 | 2022 | 39 | 0.900 |
Why?
|
| Amitriptyline | 1 | 2022 | 7 | 0.850 |
Why?
|
| Inflammation | 2 | 2016 | 503 | 0.820 |
Why?
|
| Cardiovascular System | 2 | 2012 | 38 | 0.810 |
Why?
|
| Rats | 19 | 2022 | 1604 | 0.800 |
Why?
|
| Urea | 1 | 2020 | 33 | 0.760 |
Why?
|
| Primates | 6 | 2022 | 100 | 0.760 |
Why?
|
| Thiophenes | 1 | 2020 | 21 | 0.760 |
Why?
|
| Mice | 21 | 2021 | 2368 | 0.750 |
Why?
|
| Up-Regulation | 4 | 2016 | 183 | 0.730 |
Why?
|
| Nerve Tissue Proteins | 2 | 2018 | 118 | 0.730 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 7 | 2009 | 18 | 0.700 |
Why?
|
| Analgesia | 3 | 2021 | 33 | 0.690 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 1374 | 0.670 |
Why?
|
| Cocaine-Related Disorders | 6 | 2011 | 106 | 0.660 |
Why?
|
| Piperidines | 8 | 2015 | 125 | 0.630 |
Why?
|
| Oligopeptides | 4 | 2016 | 51 | 0.630 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 101 | 0.620 |
Why?
|
| Substance P | 2 | 2015 | 22 | 0.620 |
Why?
|
| Seizures | 5 | 2011 | 61 | 0.610 |
Why?
|
| Neuropeptides | 2 | 2015 | 18 | 0.600 |
Why?
|
| Chemokines | 1 | 2016 | 35 | 0.580 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2015 | 71 | 0.580 |
Why?
|
| Neurokinin B | 2 | 2019 | 2 | 0.580 |
Why?
|
| Neurons | 3 | 2020 | 394 | 0.560 |
Why?
|
| Down-Regulation | 1 | 2016 | 142 | 0.560 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 1 | 2015 | 2 | 0.560 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 56 | 0.540 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2011 | 120 | 0.530 |
Why?
|
| Substance-Related Disorders | 2 | 2014 | 109 | 0.530 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 9 | 2013 | 13 | 0.520 |
Why?
|
| Spinal Nerves | 1 | 2015 | 65 | 0.510 |
Why?
|
| Narcotics | 3 | 2008 | 17 | 0.500 |
Why?
|
| Antidepressive Agents | 2 | 2022 | 70 | 0.500 |
Why?
|
| Rats, Sprague-Dawley | 10 | 2014 | 747 | 0.480 |
Why?
|
| Neuralgia | 2 | 2015 | 48 | 0.470 |
Why?
|
| Recombinant Proteins | 4 | 2016 | 248 | 0.450 |
Why?
|
| Morphine Dependence | 2 | 2008 | 3 | 0.440 |
Why?
|
| Sensory Receptor Cells | 3 | 2021 | 29 | 0.410 |
Why?
|
| Peptide Fragments | 6 | 2020 | 420 | 0.400 |
Why?
|
| Neurotransmitter Agents | 1 | 2011 | 26 | 0.400 |
Why?
|
| Hot Temperature | 8 | 2009 | 71 | 0.390 |
Why?
|
| Benzimidazoles | 6 | 2014 | 33 | 0.390 |
Why?
|
| Pyridines | 4 | 2019 | 78 | 0.380 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2008 | 22 | 0.380 |
Why?
|
| Dynorphins | 3 | 2015 | 9 | 0.370 |
Why?
|
| Indoles | 4 | 2019 | 58 | 0.370 |
Why?
|
| Humans | 17 | 2023 | 29013 | 0.360 |
Why?
|
| Conditioning, Operant | 4 | 2011 | 96 | 0.330 |
Why?
|
| Hydrocortisone | 2 | 2008 | 61 | 0.330 |
Why?
|
| Mutation | 1 | 2011 | 466 | 0.330 |
Why?
|
| Butorphanol | 2 | 2007 | 4 | 0.320 |
Why?
|
| Cisterna Magna | 2 | 2015 | 3 | 0.320 |
Why?
|
| Fentanyl | 5 | 2013 | 33 | 0.310 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2008 | 53 | 0.300 |
Why?
|
| Analgesics, Non-Narcotic | 5 | 2003 | 16 | 0.300 |
Why?
|
| Diuresis | 3 | 2003 | 9 | 0.300 |
Why?
|
| Macrophages | 2 | 2021 | 188 | 0.300 |
Why?
|
| Injections, Intraventricular | 5 | 2009 | 16 | 0.290 |
Why?
|
| Drug Tolerance | 2 | 2019 | 36 | 0.290 |
Why?
|
| Macaca fascicularis | 2 | 2018 | 389 | 0.280 |
Why?
|
| Drug Design | 3 | 2018 | 44 | 0.270 |
Why?
|
| Motor Activity | 3 | 2013 | 310 | 0.270 |
Why?
|
| Self Administration | 7 | 2014 | 296 | 0.270 |
Why?
|
| Respiration | 2 | 2002 | 26 | 0.260 |
Why?
|
| Pain Threshold | 2 | 2019 | 94 | 0.260 |
Why?
|
| Grooming | 1 | 2003 | 2 | 0.240 |
Why?
|
| Stereotyped Behavior | 1 | 2003 | 14 | 0.240 |
Why?
|
| Brain | 4 | 2022 | 930 | 0.240 |
Why?
|
| Heroin | 2 | 2022 | 14 | 0.240 |
Why?
|
| Benzomorphans | 4 | 2008 | 5 | 0.230 |
Why?
|
| Macaca | 2 | 2013 | 25 | 0.230 |
Why?
|
| GTP-Binding Proteins | 1 | 2003 | 24 | 0.230 |
Why?
|
| Mice, Inbred ICR | 4 | 2020 | 14 | 0.220 |
Why?
|
| Cerebral Cortex | 2 | 2003 | 141 | 0.220 |
Why?
|
| Time Factors | 7 | 2013 | 1997 | 0.220 |
Why?
|
| Rats, Wistar | 4 | 2011 | 84 | 0.220 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 13 | 0.210 |
Why?
|
| Body Temperature | 2 | 2012 | 22 | 0.210 |
Why?
|
| Interleukin-23 | 1 | 2021 | 14 | 0.200 |
Why?
|
| Interleukin-17 | 1 | 2021 | 14 | 0.200 |
Why?
|
| TRPV Cation Channels | 1 | 2021 | 19 | 0.200 |
Why?
|
| Estrogen Receptor alpha | 1 | 2021 | 50 | 0.200 |
Why?
|
| Nociceptors | 1 | 2021 | 41 | 0.200 |
Why?
|
| Interferon Type I | 1 | 2021 | 14 | 0.200 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 5 | 2013 | 24 | 0.200 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 481 | 0.200 |
Why?
|
| Polyethylene Glycols | 2 | 2011 | 65 | 0.190 |
Why?
|
| Morphinans | 3 | 2008 | 4 | 0.190 |
Why?
|
| Structure-Activity Relationship | 2 | 2018 | 82 | 0.190 |
Why?
|
| Integrins | 1 | 2020 | 20 | 0.190 |
Why?
|
| Receptors, AMPA | 1 | 2020 | 14 | 0.190 |
Why?
|
| Cell Adhesion Molecules | 1 | 2020 | 45 | 0.180 |
Why?
|
| Drug Synergism | 3 | 2009 | 67 | 0.180 |
Why?
|
| Peripheral Nervous System | 1 | 1999 | 6 | 0.180 |
Why?
|
| Sulfur Radioisotopes | 4 | 2011 | 9 | 0.180 |
Why?
|
| Central Nervous System | 1 | 1999 | 29 | 0.180 |
Why?
|
| Butyrylcholinesterase | 2 | 2010 | 15 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 152 | 0.180 |
Why?
|
| Cell Degranulation | 1 | 2019 | 4 | 0.180 |
Why?
|
| Heart Rate | 2 | 2012 | 315 | 0.180 |
Why?
|
| Drug Interactions | 4 | 2011 | 80 | 0.180 |
Why?
|
| Mast Cells | 1 | 2019 | 17 | 0.180 |
Why?
|
| Membrane Proteins | 1 | 2021 | 256 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 58 | 0.170 |
Why?
|
| Oxycodone | 1 | 2018 | 7 | 0.170 |
Why?
|
| Radioligand Assay | 5 | 2005 | 23 | 0.170 |
Why?
|
| Nerve Growth Factors | 1 | 2018 | 18 | 0.170 |
Why?
|
| Toll-Like Receptors | 1 | 2018 | 22 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 312 | 0.160 |
Why?
|
| Gene Expression | 2 | 2019 | 332 | 0.160 |
Why?
|
| Antibodies | 2 | 2009 | 53 | 0.160 |
Why?
|
| Analysis of Variance | 2 | 2011 | 454 | 0.150 |
Why?
|
| Calcium | 3 | 2019 | 296 | 0.150 |
Why?
|
| Injections, Subcutaneous | 3 | 2003 | 33 | 0.150 |
Why?
|
| Injections, Intravenous | 2 | 2011 | 73 | 0.150 |
Why?
|
| Blood Pressure | 2 | 2012 | 803 | 0.150 |
Why?
|
| Swimming | 2 | 2007 | 7 | 0.150 |
Why?
|
| Cytokines | 1 | 2018 | 243 | 0.150 |
Why?
|
| Pyrrolidines | 3 | 2008 | 13 | 0.150 |
Why?
|
| Microglia | 1 | 2016 | 48 | 0.140 |
Why?
|
| Alfentanil | 2 | 2009 | 3 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 243 | 0.140 |
Why?
|
| Reaction Time | 3 | 2008 | 121 | 0.140 |
Why?
|
| Carrageenan | 2 | 2013 | 5 | 0.140 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2015 | 3 | 0.140 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2015 | 10 | 0.140 |
Why?
|
| Pituitary-Adrenal System | 2 | 2008 | 24 | 0.140 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2008 | 34 | 0.140 |
Why?
|
| beta-Endorphin | 1 | 2015 | 2 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2018 | 465 | 0.130 |
Why?
|
| Cycloheptanes | 1 | 2015 | 1 | 0.130 |
Why?
|
| Chemokine CCL3 | 1 | 2015 | 6 | 0.130 |
Why?
|
| Hydrolysis | 2 | 2012 | 38 | 0.130 |
Why?
|
| Lumbosacral Region | 1 | 2015 | 12 | 0.130 |
Why?
|
| Azocines | 3 | 2000 | 3 | 0.130 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 22 | 0.130 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2006 | 27 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 41 | 0.130 |
Why?
|
| Haloperidol | 1 | 1995 | 5 | 0.130 |
Why?
|
| Catheterization | 1 | 2015 | 58 | 0.130 |
Why?
|
| Benzazepines | 1 | 1995 | 22 | 0.130 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 48 | 0.130 |
Why?
|
| Ileum | 2 | 2013 | 13 | 0.130 |
Why?
|
| Bacterial Proteins | 2 | 2011 | 77 | 0.120 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2010 | 60 | 0.120 |
Why?
|
| Phenalenes | 1 | 2013 | 1 | 0.120 |
Why?
|
| Rhodococcus | 2 | 2010 | 2 | 0.120 |
Why?
|
| Naloxone | 2 | 2013 | 23 | 0.120 |
Why?
|
| Binding, Competitive | 3 | 2008 | 38 | 0.110 |
Why?
|
| Anesthesia, Spinal | 1 | 2013 | 21 | 0.110 |
Why?
|
| Cells, Cultured | 3 | 2021 | 799 | 0.110 |
Why?
|
| Antipruritics | 2 | 2003 | 6 | 0.110 |
Why?
|
| Antibody Formation | 1 | 2012 | 39 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2011 | 84 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2021 | 666 | 0.100 |
Why?
|
| Bacteria | 1 | 2011 | 45 | 0.100 |
Why?
|
| Pyrroles | 2 | 2008 | 55 | 0.100 |
Why?
|
| Diazepam | 1 | 2010 | 6 | 0.100 |
Why?
|
| Autoradiography | 2 | 2011 | 47 | 0.100 |
Why?
|
| Mass Spectrometry | 2 | 2011 | 99 | 0.090 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2010 | 15 | 0.090 |
Why?
|
| Central Nervous System Agents | 1 | 2009 | 3 | 0.090 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2009 | 27 | 0.090 |
Why?
|
| Antibody Specificity | 1 | 2009 | 14 | 0.090 |
Why?
|
| Posture | 1 | 2009 | 53 | 0.080 |
Why?
|
| Hydrolases | 1 | 2008 | 6 | 0.080 |
Why?
|
| Restraint, Physical | 1 | 2008 | 10 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2009 | 63 | 0.080 |
Why?
|
| Drug Partial Agonism | 1 | 2008 | 3 | 0.080 |
Why?
|
| Enkephalins | 2 | 1998 | 7 | 0.080 |
Why?
|
| Cricetulus | 3 | 2016 | 17 | 0.080 |
Why?
|
| Cricetinae | 3 | 2016 | 58 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 711 | 0.080 |
Why?
|
| Gas Gangrene | 1 | 2007 | 1 | 0.080 |
Why?
|
| Monkey Diseases | 1 | 2007 | 18 | 0.080 |
Why?
|
| Tritium | 2 | 2004 | 17 | 0.070 |
Why?
|
| Enzyme Stability | 3 | 2011 | 8 | 0.070 |
Why?
|
| Electrocardiography | 1 | 2011 | 562 | 0.070 |
Why?
|
| Freezing Reaction, Cataleptic | 1 | 2006 | 1 | 0.070 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 35 | 0.070 |
Why?
|
| Kinetics | 3 | 2011 | 205 | 0.070 |
Why?
|
| Binding Sites | 1 | 2005 | 125 | 0.070 |
Why?
|
| Neurosecretory Systems | 1 | 2005 | 4 | 0.070 |
Why?
|
| Immune System | 1 | 2005 | 8 | 0.070 |
Why?
|
| Receptors, Neurotensin | 1 | 2004 | 2 | 0.070 |
Why?
|
| Neurotensin | 1 | 2004 | 4 | 0.070 |
Why?
|
| Nervous System | 1 | 2005 | 15 | 0.070 |
Why?
|
| Hypothermia | 1 | 2004 | 12 | 0.060 |
Why?
|
| Hypotension | 1 | 2004 | 47 | 0.060 |
Why?
|
| Histamine | 1 | 2004 | 3 | 0.060 |
Why?
|
| Atmospheric Pressure | 1 | 2004 | 12 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2004 | 34 | 0.060 |
Why?
|
| Premedication | 1 | 2003 | 10 | 0.060 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 1 | 2003 | 5 | 0.060 |
Why?
|
| Dermatology | 1 | 2005 | 154 | 0.060 |
Why?
|
| Morphine Derivatives | 2 | 2003 | 3 | 0.060 |
Why?
|
| Cinnamates | 2 | 2003 | 3 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2003 | 97 | 0.060 |
Why?
|
| Heating | 1 | 2002 | 2 | 0.050 |
Why?
|
| Tail | 1 | 2002 | 6 | 0.050 |
Why?
|
| CHO Cells | 2 | 2016 | 25 | 0.050 |
Why?
|
| Benzeneacetamides | 1 | 2001 | 3 | 0.050 |
Why?
|
| tau Proteins | 1 | 2022 | 38 | 0.050 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2021 | 6 | 0.050 |
Why?
|
| Crystallography, X-Ray | 2 | 2011 | 77 | 0.050 |
Why?
|
| Diltiazem | 1 | 2000 | 1 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 42 | 0.050 |
Why?
|
| Integrin alpha5 | 1 | 2020 | 1 | 0.050 |
Why?
|
| Integrin beta3 | 1 | 2020 | 10 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2000 | 49 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2020 | 26 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 469 | 0.050 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2020 | 26 | 0.050 |
Why?
|
| Anesthesia, Local | 1 | 2000 | 16 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2020 | 19 | 0.050 |
Why?
|
| Hypersensitivity | 1 | 2020 | 25 | 0.050 |
Why?
|
| Dogs | 1 | 2020 | 117 | 0.050 |
Why?
|
| Temperature | 2 | 2010 | 55 | 0.050 |
Why?
|
| Injections | 1 | 1999 | 61 | 0.040 |
Why?
|
| Species Specificity | 2 | 2011 | 84 | 0.040 |
Why?
|
| Guinea Pigs | 2 | 2013 | 12 | 0.040 |
Why?
|
| Toluene 2,4-Diisocyanate | 1 | 2019 | 1 | 0.040 |
Why?
|
| Injections, Intradermal | 1 | 2019 | 7 | 0.040 |
Why?
|
| Receptors, Drug | 1 | 1999 | 14 | 0.040 |
Why?
|
| Sex Factors | 1 | 2021 | 626 | 0.040 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2019 | 11 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2010 | 178 | 0.040 |
Why?
|
| Receptors, Cannabinoid | 1 | 1999 | 26 | 0.040 |
Why?
|
| Peptides | 1 | 1999 | 118 | 0.040 |
Why?
|
| Pyrazoles | 1 | 1999 | 64 | 0.040 |
Why?
|
| Ganglia, Spinal | 1 | 2019 | 63 | 0.040 |
Why?
|
| Eating | 1 | 2019 | 73 | 0.040 |
Why?
|
| Dermatitis, Atopic | 1 | 2020 | 86 | 0.040 |
Why?
|
| Brain Chemistry | 1 | 1998 | 30 | 0.040 |
Why?
|
| Skin | 1 | 2020 | 203 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 103 | 0.040 |
Why?
|
| Tyrphostins | 1 | 2015 | 2 | 0.030 |
Why?
|
| Aging | 1 | 2022 | 880 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 107 | 0.030 |
Why?
|
| Calcium Channels, N-Type | 1 | 2014 | 4 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 225 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2014 | 56 | 0.030 |
Why?
|
| Receptors, Nicotinic | 1 | 2015 | 60 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 90 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2013 | 102 | 0.030 |
Why?
|
| Protein Binding | 1 | 2013 | 199 | 0.030 |
Why?
|
| Sweetening Agents | 1 | 2011 | 8 | 0.030 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 24 | 0.030 |
Why?
|
| Sucrose | 1 | 2011 | 17 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 2011 | 17 | 0.030 |
Why?
|
| Calibration | 1 | 2011 | 25 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2011 | 41 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 46 | 0.030 |
Why?
|
| Protein Stability | 1 | 2011 | 26 | 0.030 |
Why?
|
| Ketamine | 1 | 2011 | 20 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2011 | 34 | 0.030 |
Why?
|
| Food Preferences | 1 | 2011 | 35 | 0.030 |
Why?
|
| Reinforcement Schedule | 1 | 2011 | 60 | 0.030 |
Why?
|
| Methylphenidate | 1 | 2011 | 36 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2010 | 18 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 281 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2010 | 47 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 286 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2011 | 114 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 85 | 0.020 |
Why?
|
| Trypsin | 1 | 2009 | 12 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2010 | 82 | 0.020 |
Why?
|
| Nalbuphine | 2 | 2000 | 2 | 0.020 |
Why?
|
| Quantum Theory | 1 | 2008 | 2 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 21 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2008 | 84 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2008 | 45 | 0.020 |
Why?
|
| Middle Aged | 1 | 2022 | 10805 | 0.020 |
Why?
|
| Clostridium perfringens | 1 | 2007 | 2 | 0.020 |
Why?
|
| Kallidin | 1 | 2007 | 1 | 0.020 |
Why?
|
| Receptor, Bradykinin B1 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2007 | 11 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2008 | 202 | 0.020 |
Why?
|
| Naproxen | 1 | 2007 | 8 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2007 | 14 | 0.020 |
Why?
|
| Bradykinin | 1 | 2007 | 18 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2007 | 53 | 0.020 |
Why?
|
| Debridement | 1 | 2007 | 43 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 192 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2007 | 103 | 0.020 |
Why?
|
| Cell Line | 1 | 2007 | 449 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2007 | 425 | 0.020 |
Why?
|
| Vas Deferens | 1 | 2004 | 1 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 2004 | 114 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 531 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 680 | 0.010 |
Why?
|
| Ethylketocyclazocine | 1 | 2001 | 1 | 0.010 |
Why?
|
| Membranes | 1 | 2001 | 11 | 0.010 |
Why?
|
| Muscle Relaxation | 1 | 2001 | 7 | 0.010 |
Why?
|
| Prolactin | 1 | 2001 | 10 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 2001 | 8 | 0.010 |
Why?
|
| Clonidine | 1 | 2000 | 60 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1999 | 6 | 0.010 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 1999 | 5 | 0.010 |
Why?
|
| Benzofurans | 1 | 1998 | 5 | 0.010 |
Why?
|